Emgality provided significant reductions in the average number of weekly cluster headache attacks: -8.7 with Emgality vs -5.2 with placebo (baseline: 17.8 vs 17.3)1a

Mean Reduction in Weekly Cluster Headache Attack Frequency (over Weeks 1 to 3)1,2a

See study design for episodic cluster headache.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Emgality can make a difference as early as the first dose1,3,4

Mean Change in Weekly Cluster Headache Attack Frequency Over Weeks 1 to 31,3,4

See study design for episodic cluster headache.

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

For your patients with episodic cluster headache,

Emgality cut weekly cluster headache attacks in half or more for most patients at Week 31

71.4% of patients on Emgality 300 mg achieved a ≥50% reduction from baseline vs 52.6% of patients on placebo (p=0.046)1

Percentage of Patients Achieving ≥50% Reduction in
Weekly Cluster Headache Attack Frequency at Week 31

See study design for episodic cluster headache.

SELECT IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

References

  1. Emgality. Prescribing Information. Lilly USA, LLC.
  2. Data on File. Lilly USA, LLC. C-GZ-US-0120.
  3. Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019; 381(2):132-141.
  4. Data on File. Lilly USA, LLC. C-GZ-US-0093.

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache